ReviewAntioxidants & redox signaling2018
Mn Porphyrin-Based Redox-Active Drugs: Differential Effects as Cancer Therapeutics and Protectors of Normal Tissue Against Oxidative Injury.
Review in Antioxidants & redox signaling, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
75 citing papers in PubMed, 1 synthesis or guideline pooled it, 146 citations in OpenAlex.
- Superoxide Dismutase Administration: A Review of Proposed Human Uses.Molecules (Basel, Switzerland) · 2021Pooled it
- The Influence of the Central Metal (Zn) in the Porphyrin Skeleton on the Mechanism Induced by Photodynamic Therapy.Cancers · 2026Review
- BMX-001 acts as a selective chemoradioprotector in rectal cancer.Redox biochemistry and chemistry · 2026Article
- Radiomitigators: Breakthroughs in Post-Radiation Recovery.Antioxidants (Basel, Switzerland) · 2026Review
- An Antioxidant Cocktail ofAntioxidants (Basel, Switzerland) · 2026Article
- Transmetalation in Cancer Pharmacology.International journal of molecular sciences · 2025Review
- Mn(III) Porphyrin MnTE-2-PyPACS infectious diseases · 2025Article
- Colorectal Cancer at the Crossroads: The Good, the Bad, and the Future of Platinum-Based Drugs.Chemical reviews · 2025Review
- Radioprotectors & mitigators in radiation therapy: Harnessing diverse pathways for optimizing clinical outcomes.The Indian journal of medical research · 2025Review
- Manganese Porphyrin Reduces Oxidative Stress in Vulnerable Parkin-NullAntioxidants (Basel, Switzerland) · 2025Article
- Therapeutic Potential of BMX-001 for Preventing Chemotherapy-Induced Peripheral Neuropathic Pain.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Manganese Porphyrin Treatment Improves Redox Status Caused by Acute Compressive Spinal Cord Trauma.Antioxidants (Basel, Switzerland) · 2025Article
- Treatment with Manganese Porphyrin, MnTnBuOE-2-PyPPharmaceuticals (Basel, Switzerland) · 2025Article
- Suppression of Paclitaxel-Induced Neuropathy and Ovarian Tumor Growth by Mn Porphyrin, MnTnBuOE-2-PyPOxidative medicine and cellular longevity · 2025Article
- High-dose Ascorbate Exhibits Anti-proliferative and Anti-invasive Effects Dependent on PTEN/AKT/mTOR Pathway in Endometrial CancerInternational journal of biological sciences · 2025Article
- MnSOD Mimetics in Therapy: Exploring Their Role in Combating Oxidative Stress-Related Diseases.Antioxidants (Basel, Switzerland) · 2024Review
- Review
- Article
- Systemic Effects of Photoactivated 5,10,15,20-tetrakis(Biotech (Basel (Switzerland)) · 2024Article
- Evaluation of the Therapeutic Potential of Amantadine in a Vincristine-Induced Peripheral Neuropathy Model in Rats.Animals : an open access journal from MDPI · 2024Article
15 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
significanceAfter approximatelty three decades of research, two Mn(III) porphyrins (MnPs), MnTE-2-PyP CRITICAL ISSUES: Differential effects of MnPs on normal versus tumor cells/tissues, which support their translation into clinic, arise from differences in their accumulation and redox environment of such tissues. This in turn results in different yields of MnP-driven modifications of proteins. Thus far, direct evidence for such modification of NF-κB, mitogen-activated protein kinases (MAPK), phosphatases, Nrf2, and endogenous antioxidative defenses was provided in tumor, while indirect evidence shows the modification of NF-κB and Nrf2 translational activities by MnPs in normal tissue. FUTURE DIRECTIONS: Studies that simultaneously explore differential effects in same animal are lacking, while they are essential for understanding of extremely intricate interactions of metal-based drugs with complex cellular networks of normal and cancer cells/tissues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.